Truist raised the firm’s price target on Merck to $122 from $116 and keeps a Buy rating on the shares after its Q2 results. The company’s base business is continuing to support growth as Merck executes on key products such as Keytruda/Gardasil, the analyst tells investors in a research note. Truist adds that it sees next leg of growth for the company coming from Cardiovascular Disease and Inflammation and Immunology programs.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK: